BioSpace News Archive

Endo International plc announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren’s contracture, a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans.

Areteia Therapeutics announces two key leadership appointments: Dr. Eric Bradford M.D. as Chief Medical Officer and Robin Walker J.D. as Chief Legal Officer and Corporate Secretary.

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options.

Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that Aesther has entered into two separate Backstop Agreements for a total of up to $80 million, with the addition of up to $40 million from Meteora Special Opportunity Fund I, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Capital Partners, LP in connection with its proposed business combination with Ocean.

Genenta Science, a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences.

Ikena Oncology, Inc. announced that two abstracts highlighting the company’s Aryl Hydrocarbon Receptor antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.

Agenus Inc. announced the Company will present new data on its growing portfolio of clinical-stage immuno-oncology programs at the Society for Immunotherapy of Cancer 37th Annual Meeting, to be held November 8-12 in Boston, MA and virtually.

PDS Biotechnology Corporation announced that two abstracts reporting the results of clinical development studies of PDS0101 have been accepted for presentation at the 37th Annual Meeting for the Society for Immunotherapy of Cancer being held November 8-12, 2022, in Boston.

Immutep Limited will announce first interim data from the INSIGHT-003 clinical trial in a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting 2022, which is taking place in person in Boston, US and virtually from 8 to 12 November 2022.

Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced two poster presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting, being held November 10-12, 2022, in Boston, MA.